Hans Skovgaard Poulsen, MD, DMSc
| 1988 | Specialist in Oncology and Radiotherapy |
| 1984 | Doctoral Thesis (DMSc.), University of Aarhus, Denmark |
| 1981-82 | Senior Research Fellow in Pathology and Oncology, Columbia Presbyterian Hospital, College of Physician and Surgeons, New York, USA |
| 1978 | MD, University of Aarhus, Denmark |
| 1990-1994 | President, the Danish Association for Cancer Research |
| 1992-1996 | Initiated Dansk Kræftforsknings Fond and member of the Board of Directors |
| 1993- | Member of EORTC’s Brain tumor Group |
| 1995-1997 | Member of the Scientific Committee of Ethics for Copenhagen and Frederiksberg |
| 1994-2000 | Member of the Editorial Board of Lung Cancer |
| 1996-2002: | Member of the scientific Board, The Danish Cancer Society |
| 1996-2000 | Member of the Board, the European Association of Neuro-Oncology |
| 1997-2006 | Secretary, the Danish Brain Tumor Study Group (DBTSG) |
| 1998-2006 | Member of the Editorial Board of Neuro-Oncology |
| 1999-2007 | Board member, Patent administration, Biotechnology, University Hospital, Copenhagen |
| 1999-2002 | CSO, Odin Medical A/S |
| 2000 | President, EANO 2000 |
| 2000-2007 | President, Scandinavian Neuro-Oncology Group (SNOG) |
| 2003- | Member of the National Board of Patients´ Complaints of the Danish Public Health Authorities. |
| 2006- | Board member of Danish Graduate School in Clinical Oncology |
| 2007- | Member of the scientific Board, The Norwegian Cancer Society |
| 2009- | Visiting Professor at The Preston Robert Tisch Brain Tumor Center at Duke University |
| 2009- | EU Evaluation Commission, FP7-Health 2010 |
| 2010- | Member of the Scientific Advisory Board, University of Catanzaro Magna Græcia, Catanzaro, Italy |
| 2010- | Member of the executive board, Danish Neurooncology group -DNOG |
| 2012- | EU FP7: Glioma Actively Personalized Vaccine Consortium; granted by EU |
| 2012- | Coordinator of Neurooncology, Copenhagen Comprehensive Cancer Center - 4C |
| 1976 | Gold medal for Prize paper in Oncology, University of Aarhus |
| 1986 | ESTRO travelling award |
| 1998 | Kaj Bunch-Jensen and Allis Bunch-Jensen’s award for Cancer Research |
| 2008 | The honouree award of the Danish Society for Cancer Research |
| 159 | Original articles in scientific journals with peer-review |
| 6 | Submitted papers to scientific journals with peer-review |
| 9 | Original articles in journals without peer-review |
| 8 | Book chapters |
| 3 | Patents |
| 1. | Poulsen HS: Demonstration of hormonal sensitivity in gynaecomastic tissue by thymidine incorporation in vitro. Acta path microbiol scand (section A), 85: 19-24, 1977. |
| 2. | Overgaard J, Poulsen HS: Brief Communication: Effect of hyperthermia and environmental acidity on the proteolytic activity in murine ascites tumor cells. J Natl Cancer Inst, 58: 1159-1161, 1977. |
| 3. | Poulsen HS: Absence of association between oestrogen-receptor content and in vitro oestrogen sensitivity in human breast cancer. Acta path microbiol scand (section A), 86: 169-172, 1978 |
| 4. | Nielsen HE, Poulsen HS, Olsen KJ, Gadeberg CC, Schultz H: Bone mineral content and estrogen receptors in patients with breast cancer. Europ. J. Cancer, 15: 703-707, 1979. |
| 5. | Poulsen HS, Schultz H, Bichel P: Oestrogen-receptor determinations on fine-needle aspirations from malignant tumours of the breast. Europ J. Cancer, 15: 1431-1438, 1979. |
| 6. | Mørch-Jørgensen L, Poulsen HS, Larsson L-I: Formaldehyde-Fluorescamine- induced fluorescence of mammary carcinoma cells. Lack of concordance with occurence of Oestrogen-binding proteins. Virchows Arch B Cell Path, 30; 281-287, 1979 |
| 7. | Poulsen HS, Schultz HP, Hansen ES: Østrogen receptorbestemmelse på malignt humant mammavæv. Hvorledes undgås falsk negative resultater? Ugeskr. Læg, 143: 192-194, 1981. |
| 8. | Poulsen HS: Oestrogen Receptor Assay-Limitation of the Method. Europ. J. Cancer 17: 495-501, 1981 |
| 9. | Poulsen HS, Jensen J, Hermansen C: Human breast cancer: Heterogeneity of estrogen binding sites. Cancer, 48: 1791-1793, 1981. |
| 10. | Poulsen HS, Frederiksen P: Glucose-6-phosphate dehydrogenase activity in human breast cancer. Lack of association with estrogen receptor content. Acta path. microbiol scand. (section A), 89: 263-270, 1981. |
| 11. | Poulsen HS, Bichel P, Andersen J: Short-term culture of human breast cancer: In vitro effects of hormones related to patient response. Br J Cancer, 46: 67-74, 1982. |
| 12. | Bichel P, Poulsen HS, Andersen J: Estrogen receptor content and ploidy of human mammary carcinoma. Cancer, 50: 1771 - 1774, 1982 |
| 13. | Poulsen HS, L. Ozzello L, Andersen J: Oestrogen receptors in human breast cancer. Problems of correlation with histopathological features. Virchows Arch ( Pathol Anat ), 397: 103-108, 1982. |
| 14. | Poulsen HS: Estrogen receptors in human breast cancer. Comparative features of the hydroxylapatite- and Dextran-coated charcoal assay. Eur J Cancer Clin Oncol, 18: 1075-1079, 1982. |
| 15. | Poulsen HS: In vitro tests and hormonal treatment of breast cancer. Progress in Surgical Pathology, pp 37-65., 1983. |
| 16. | Hermansen C, Poulsen HS, Jensen J, Langfeldt JB, Steenskov V, Frederiksen P, Jensen OM: Palpable breast tumours: "Triple diagnosis" and operative strategy, Results of a prospective study. Acta Chir Scand, 150: 625-628, 1984 |
| 17. | Poulsen HS, Bukh A, Rytter L, Thomsen K, Ørntoft T, Andersen HU, Møller NPH, Brünner N: Oestrogen receptor assay. False positive analysis? Acta Radiologica Oncology, 23: 109-117, 1984. |
| 18. | Jacobsen A, Poulsen HS, Madsen EL, Petersen SE, Hansen HS: Ploidy level of human breast carcinoma. Relation to histopathologic features and hormone receptor content. Acta Radiologica Oncology, 23: 103-107, 1984. |
| 19. | Thorpe SM, Olsen K, Pedersen KO, Poulsen HS, Rose C: Quality control of estrogen and progesterone receptor analyses in Denmark. Res Results Cancer Res, 91: 91-93, 1984. |
| 20. | Poulsen HS, Ozzello L, King WJ, Greene GL: The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissue. J Histochem Cyto¬chem, 33: 87-92, 1985. |
| 21. | Ørntoft TF, Mors NPO, Eriksen G, Jacobsen NO, Poulsen HS: Comparative immunoperoxidase demonstration of T-antigens in human colorectal carcinomas and morphologically abnormal mucosa. Cancer Res, 45: 447-452, 1985. |
| 22. | Brünner N, Spang-Thomsen M, Poulsen HS , Engelholm SA, Nielsen A, Vindeløv L: Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude mice. Int J Cancer, 35: 59-64, 1985. |
| 23. | Brünner N, Bastert GB, Poulsen HS, Spang-Thomsen M, Engelholm SA, Vindeløv L, Nielsen A, Tommerup N, Elling F: Characterization of the T61 human breast carcinoma established in nude mice. Eur J Cancer Clin Oncol, 21: 833-843, 1985. |
| 24. | Nielsen HE, Saksø P, Poulsen HS, Gadeberg CC: Bone mineral content and estrogen receptors in women with breast tumors. Acta Radiologica Oncology, 24: 247-251, 1985. |
| 25. | Poulsen HS, Hermansen C, Andersen JA, Andersen HU, Jensen J: Gynecomasty: Estrogen and androgen receptors. A clinical-pathological inves¬tigation. Acta path. microbiol. immunol. scand. (section A), 93: 229-233, 1985. |
| 26. | Nielsen NSM, Poulsen HS: Relation between mammagraphic findings and hormonal receptor content in breast cancer. Am J Roentgenology, 145: 501-504, 1985. |
| 27. | Andersen J, Ørntoft TF, Poulsen HS: Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies. Br J Cancer, 53: 691-694, 1986 |
| 28. | Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Poulsen HS, Andersen AP, Loft H, Dombernowsky P, Andersen KW: Com¬bined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. Breast Cancer Res Treat, 7: 45-50, 1986. |
| 29. | Hermansen C, Poulsen HS , Jensen J, Langfeldt B, Steenskov V, Frederiksen P, Jensen OM: Diagnostic Reliability of Combined Physical Examination, Mammography and Fine-Needle Puncture ("Triple Test") in Breast Tumors. A Prospective Study. Cancer, 60: 1866-1871, 1987. |
| 30. | Andersen J, Andersen JA, Ørntoft TF, Poulsen HS: Gynecomastia: Immunohistochemical demonstration of estrogen receptors. Acta path. microbiol. immunol. scand.( Section A ), 95: 263-267, 1987. |
| 31. | Andersen J, Poulsen HS: Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: Correlation with clinical endocrine response. J. steroid Biochem, 30: 337-339, 1988. |
| 32. | Bentzen SM , Poulsen HS, Kaae S, Jensen OM, Johansen H, Mouridsen HT, Daugaard S, Arnoldi C: Prognostic factors in osteosarcomas. A regression analysis. Cancer, 62: 194-202, 1988. |
| 33. | Jacobsen A, Hansen V, Poulsen HS: DNA profile and steroid receptor content of human ovarian cancer. Eur J Gynaec Oncol, 6: 461-463, 1988. |
| 34. | Andersen J, Bentzen SM, Poulsen HS: Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. Eur J Cancer Clin Oncol, 24: 377-384, 1988. |
| 35. | Bukh A, Agua MT, Krarup N, Poulsen HS, Nordentoft AM, Møller NP: A prospective study of circulating immune complexes in patients with breast cancer. Int. J Cancer, marts 15; 41,364-70, 1988. |
| 36. | Thorpe SM, Poulsen HS, Pedersen KO, Rose C: Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark. Eur J Cancer Clin Oncol, 24: 1263-1269, 1988. |
| 37. | Andersen J, Ørntoft TF, Poulsen HS: Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by use of a monoclonal antibody to ER1. J histochem Cytochem, 36: 1553-1560, 1988. |
| 38. | Andersen J, Poulsen HS: Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncologica, 27: 761-765, 1988 |
| 39. | Thorpe SM, Poulsen HS, Pedersen KO, Rose C: Quality control of receptor analyses of breast cancer tissue in Denmark. Acta Oncologica, 27: 621 - 625, 1988. |
| 40. | Andersen J, Skovbon H, Poulsen HS: Immunocytochemical determination of the estrogen regulated protein Mr 24.000 in primary breast cancer and response to endocrine therapy. Eur J Cancer Clin Oncol, 25: 641-643, 1989 |
| 41. | Scopsi L, Balslev E, Brünner N, Poulsen HS, Andersen J, Rank F, Larsson L-I: Immunoreactive opioid peptides in human breast cancer. American J Pathol, 134, 2: 473-479, 1989. |
| 42. | Andersen J, Poulsen HS: Immunohistochemical Estrogen Receptor Determination in Paraffin Embedded Tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer, 64: 1901 - 1908, 1989 |
| 43. | Jørgensen LJ, Poulsen HS, Nordentoft AM, Jensen OM, Sneppen O: Sarcoma Synoviale. Ugeskr Læger, 151: 1325-1328, 1989. |
| 44. | Nielsen OS, Poulsen HS: Knoglemetastaser. Ugeskr Læger, 151: 362-365, 1989. |
| 45. | Poulsen HS, Nielsen OS, Klee M, Rørth M: Palliative irradiation of Bone Metastases. Cancer Treat Review, 16: 41-48, 1989 |
| 46. | Rørth M, Poulsen HS: Behandling af Kræftsygdomme. Ugeskr Læger, 151: 325-330, 1989. |
| 47. | Damstrup L, Rørth M, Poulsen HS: Growth factors and growth factor receptors in human malignancies, with special reference to human lung cancer: a review. Lung Cancer, 5: 49-68, 1989 |
| 48. | Poulsen HS: Cancer cell cultures and their clinical application. Reviews Endocrine-Related Cancer, 33: 17-22, 1989. |
| 49. | Krarup-Hansen A, Poulsen HS: Extra-visceral soft tissue sarcomas in adults: local treatment, with special reference to irradiation. Cancer Treat Reviews, 16: 221-246, 1989 |
| 50. | Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, Thorpe SM, Poulsen HS: The prognostic value of immunohistochemical estrogen receptor analysis inparaffin-embedded and frozen sections versus that of Steroid-binding assays. Eur J Cancer Clin Oncol, 26: 442-449, 1990. |
| 51. | Mouridsen HT, Dombernowsky P, Jensen OM, Johansen H, Lund B, Nordentoft A,, Poulsen HS,Schiødt T, Sneppen O: Sarkom Behandling i Danmark. Ugeskr Læger, 152: 989-992, 1990 |
| 52. | Andersen J, Thorpe SM, Rose C, Christensen I, Rasmussen BB, Poulsen HS : Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. Acta Oncologica, 30: 685-690, 1991 |
| 53. | Becker U, Andersen J, Poulsen HS, Burcharth F, Gluud C, Horn T: Enzyme immunoassay of oestrogen receptors in needle biopsies from human liver. Liver, 11: 292-299, 1991. |
| 54. | Hippe E, Jønsson V, von der Maase H, Mathiesen JC, Poulsen HS: Homoeostatic response criteria for cancer therapy. Eur J Cancer, 27: 1715-1716, 1991. |
| 55. | Nørgaard P, Poulsen HS: Glucocorticoid receptors in human malignancies: A review. Ann Oncol, 2: 541-557, 1991 |
| 56. | Nielsen NSM, Andersen J, Poulsen HS, Mathiessen O: Prediction of hormone responsiveness by mammographic parenchymal pattern in advanced primary breast cancer. Breast Cancer Res Treat, 23: 219-222, 1992 |
| 57. | Damstrup L, Andersen J, Kufe DW, Hayes DF, Poulsen HS: Immunocyt-ochemical determination of the Estrogen-regulated proteins Mr 24.000,Mr 52.000 and DF3 breast cancer associated antigen:Clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol, 3: 71-77, 1992 |
| 58. | Becker U, Andersen J, Poulsen HS, Horn T: Variation in hepatic estrogen receptor concentrations in patients with liver disease: A multivariate analysis. Scand J Gastroenterol, 27: 355-361, 1992 |
| 59. | Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Expression of the Epidermal Growth Factor Receptor in Human Small Cell Lung Cancer Cell Lines. Cancer Res 52: 3089- 3093, 1992. |
| 60. | Nørgaard P, Damstrup L, Spang-Thomsen M, Poulsen HS: Trans¬forming growth factor- b. En potent multifunktionel vækstfaktor for normale og maligne celler. Ugeskr Læger, 154: 3494-3498, 1992. |
| 61. | Becker U, Andersen J, Poulsen HS,Horn T: Hepatic cytosolic oestrogen receptors in patients with liver disease. J Intern Med. Feb; 233(2), 165-72, 1993 |
| 62. | Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Expression of transforming growth factor b (TGF b) receptors of TGF b 1, TGF b 2, and TGFb 3 in human small cell lung cancer cell lines. Br J Cancer, 67: 1015-1021, 1993. |
| 63. | Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Growthsuppresion by transforming growth factor b of human small cell lung cancer cell lines is associated with expression of type II receptor. Br J Cancer, 69: 802 - 808, 1994 |
| 64. | Damstrup L, Poulsen HS: Review of the curative role of radiotherapy in the treatment of non - small cell lung cancer. Lung Cancer, 11: 153- 178, 1994 |
| 65. | Bouchelouche PN, Berild D, Nielsen OH, Elmgreen J, Poulsen HS : Leukotriene B4 receptor levels and intracellular calcium, signalling in polymorpho- nuclear leukocytes from patients with Chron’s disease. Eur J Gatroent Hepatol, 7: 349 - 356, 1995. |
| 66. | Nørgaard P, Hougaard S, Spang-Thomsen M, Poulsen HS: Transforming Growth Factor b and Cancer. Cancer Treat Reviews, 21: 367 - 403, 1995 |
| 67. | Poulsen HS, Sørensen JB: Management of patients with Lung Cancer. Oncology in Practice, 1995 |
| 68. | Nørgaard P, Spang-Thomsen M, Poulsen HS: Expression and autoregulation of transforming growth factor b receptor mRNA in small- cell lung cancer cell lines. Br J Cancer, 73: 1037 - 1043, 1996. |
| 69. | Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Acquired TGF -b1 sensitivity and TGF-b1 expression in cell lines established from a single small cell lung cancer patient during clinical progression. Lung Cancer, 14: 63 - 73, 1996 |
| 70. | Kristensen CA, Jensen PB, Poulsen HS, Hansen HH: Small Cell Lung Cancer: Biological and therapeutic aspects. Critical Review in Oncology/ Hæmatol, 22: 27 - 60, 1996 |
| 71. | Pedersen AN, Højer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW: The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Immun Methods, 203: 55 - 65, 1997 |
| 72. | Krarup M, Poulsen HS, Spang-Thomsen M: Cellular Radiosensitivity of small-cell lung cancer cell lines. Int J Radiation Oncology Biol Phys, 38: 191 - 196, 1997 |
| 73. | Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol, 8: 1197 - 1206, 1997 |
| 74. | Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, Poulsen HS, Spang-Thomsen M, Nørgaard P: Loss of the retinoblastoma protein - related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci, 94: 6933 - 6938, 1997 |
| 75. | Damstrup L, Voldborg BR, Spang-Thomsen M, Brunner N, H. Poulsen HS: In vitro invasion of small - cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer, 78: 631 - 640, 1998. |
| 76. | Hougaard S, Krarup M, Nørgaard P, Damstrup L, Spang-Thomsen M, Poulsen HS: High value of the radiobiological parameter Dq correlates to expression of the transforming growth factor b type II receptor in a panel of small cell lung cancer cell lines. Lung Cancer, 20, 65 - 69, 1998 |
| 77. | Lassen U, Andersen P, Daugaard G, Holm S, Jensen M, Svarre C, Poulsen HS, Paulson OB: Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission topography. Clin. Cancer Res., 501-3, 1998 |
| 78. | Lund EL, Spang-Thomsen M, Poulsen HS, Kristjansen PEG: Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neu Scand, 97: 52 - 62, 1998 |
| 79. | Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS, Wiley HS, Coffey RJ: Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer, 80: 1012 - 1019, 1999. |
| 80. | Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL: Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) apha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res, 5: 35 - 42, 1999 |
| 81. | Hougaard S, Nørgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, Poulsen HS: Inactivation of the transforming growth factor b type II receptor in human small cell lungcancer cell lines. Br J Cancer, 79: 1005 - 1011, 1999 |
| 82. | Lassen U, Kristjansen PEG, Wagner Aa, Kosteljanetz M, Poulsen HS: Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J NeuroOncol, 43: 161 - 166, 1999 |
| 83. | Schmiegelow M, Weber L, Lassen S, Poulsen HS , Hertz H, Müller J: Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors. Med Pediatr Oncol, 33: 564 - 571, 1999. |
| 84. | Law BK, Nørgaard P, Gnudi L, Kahn BB, Poulsen HS, Moses HL: Inhibition of DNA Synthesis by a Farnesyltransferase Inhibitor Involves Inhibition of the p70 (s6k) Pathway J Biol Chem, 19: 4743 - 4748, 1999 |
| 85. | Nørgaard P, Law BK, Poulsen HS, Moses HL: Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation. Ann N Y Acad Sci, 886: 265-8, 1999 |
| 86. | Frederiksen KS, Petri A, Abrahamsen N, Damstrup L, Poulsen HS: Gene therapy for Lung Cancer. Lung Cancer, 23: 191- 107, 1999 |
| 87. | Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS: Gene delivery by an epidermal growth factor/ DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther, 7: 262 - 268, 2000. |
| 88. | Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K., Hertz H, Müller JR: Biological Effective Dose-GH-Deficiency. Cranial radiotherapy of childhood brain tumors: Growth hormone deficiency and the relation to the biological effective dose of irradiation in a large population based study.Clin Endocrinol (Oxf);53(2): 191-7, 2000 |
| 89. | Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H, Müller JR:Growth Hormone Response to a Growth Hormone Releasing Hormone Stimulation Test in a Population Based Study Following Irradiation of Childhood Brain Tumours. Horm Res, 54(2): 53-59, 2000 |
| 90. | Pedersen MW, Thykjær T, Ørntoft TF, Damstrup L, Poulsen HS: Profile of differentially expressed genes mediated by the Type III Epidermal Growth Factor Receptor mutation in small cell lung cancer cell line. Br J Cancer; 85( 8 ): 1211 - 1218, 2001 |
| 91. | Schmiegelow M, Lassen S, Poulsen HS, Schmiegelow K, Hertz H, Andersson AM, Skakkebæk NE, Müller J: Gonodal status in male survivors following childhood brain tumors. J Clin Endocrin Metab, 86: 2446 - 2452, 2001 |
| 92. | Wurtzen PA, Pedersen L, Poulsen HS, Claesson MH: Specific killing of P53 mutated tumor cell lines by cross-reactive huam HLA-A2-restricted P53-specific CTL line. Int J Cancer, 93: 855-861, 2001 |
| 93. | Pedersen MW, Meltorn M, Poulsen HS: The Type III EGF receptor growth factor mutation. Ann Oncol, 12: 745 – 760, 2001. |
| 94. | Damstrup L, Pedersen MW, Bastholm L, Elling F, Poulsen HS: Epidermal Growth Factor Receptor Mutation Type III transfected into small cell lung cancer cell line is predominantly localized at the cell surface and enhance tumorigeneity. Int J Cancer, 97: 7 -14, 2002. |
| 95. | Mortensen S, Sørensen SB, Poulsen HS: Genterapi og cancer. Ugskrf Læger, 164: 1785 - 1790, 2002. |
| 96. | Pedersen MW, Poulsen HS: Epidermal Growth Factor Receptor in Cancer Therapy. Science & Medicine, august: 206- 217, 2002 |
| 97. | Schmiegelow M, Feldt-Rasmussen U, Rasmussen ÅK, Hertz H, Poulsen HS, Müller J: Thyroid function in Childhood brain tumor. A population based study of Thyroid function after Radiotherapy and Chemotherapy for a Childhood brain tumor. J Clin Endocrinol Metab, 88(1): 136-40, 2003. |
| 98. | Hansen LRT, Lundin C, Helleday T, Poulsen HS, Petersen LN, Spang-Thomsen M: DNA repair rate and etoposide resistance in two tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer, 40(2): 157-64, 2003 |
| 99. | Pedersen N, Mortensen S, Sørensen SB, Pedersen MW, Rieneck K, Bovin LF, Poulsen HS: Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 63(8):1943-53. 2003 |
| 100. | Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen X, Xu T, Poulsen HS, Young MF, Heegaard M: Biglycan Deficiency interferes with overiectomy-induced bone loss. J Bone Miner Res, 18(12): 2152-2158, 2003 |
| 101. | Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulsen HS, Müller J: Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients treated with Cranial Radiotherapy for a Childhood Brain Tumor. J Clin Endocrinol Metab, 88(7): 3149-54, 2003. |
| 102. | Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG: Preparation and purification of cationic nanospheres - effects on particle size, physical stability and cell toxicity. Int J Pharm, 254: 83-87, 2003. |
| 103. | Pedersen N, Poulsen HS: New drug modalities for treatment of lung cancer. Review Series Oncology, 2/2003: 2-6, 2003. |
| 104. | Pedersen MW, Tkach V, Pedersen N, Berezin V and Poulsen HS: Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases cell motility. Int J Cancer, 108: 643-653, 2004. |
| 105. | Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Thomsen J, Johansen C: Cellular telephone use and risk for acoustic neurinoma. Am J Epidemiology, 159(3): 277-83, 2004 |
| 106. | Pedersen MW, Pedersen N, Damstrup L, Villingshøj M, Sønder SU, Rieneck K, Bovin LF, Spang-Thomsen M, Poulsen HS: Analysis of the epidermal growth factor receptor specific transcriptome: effect of expression level and an activating mutation. J Cell Biocem, 96(2): 412-427, 2005 |
| 107. | Poulsen TT, Pedersen N, Perin MS, Celia K, Hansen CK, Poulsen HS: Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin. Lung Cancer, 50(3): 329-337, 2005 |
| 108. | Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Boice J, McLaughlin, Johansen C: Cellular telephone and risk for brain tumors. A population-based, incident case-control study. Neurology, 64(7): 1189-95, 2005 |
| 109. | Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS: Differential response to gefinitib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer, 93: 915-923, 2005 |
| 110. | Poulsen TT, Pedersen N, Poulsen HS: Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin Lung Cancer, 6: 227-236, 2005 |
| 111. | Pedersen N, Hansen SE, Heydenreich AV, Kristensen HG. and Poulsen HS: Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur J Pharm Biopharm, 62:155-162, 2006 |
| 112. | Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS: The insulinoma-associated 1:a novel promoter for targeted cancer gene therapy for small cell lung cancer. Cancer Gene Ther, 13: 375-384, 2006. |
| 113. | Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, Poulsen HS, Larsen LA: Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer, 52:281-290, 2006. |
| 114. | Andersen PB, Blinkenberg M, Lassen U, Kosteljanetz M, Wagner A, Poulsen HS, Sørensen PS, Paulson OB: A prospective PET study of patients with glioblastoma multiforme. Acta Neurol Scand, 113(6): 412-8, 2006. |
| 115. | Pedersen MW, Poulsen HS: Mutationer i EGF receptoren: struktur og tumorbiologisk relevans. Ugeskr Læger, 168:2 354-2361, 2006 |
| 116. | Poulsen HS: Gliomer hos voksne: Primær ikke kirurgisk behandling. Ugeskr Læger, 168: 4082-5, 2006 |
| 117. | Spindler K-LG, Olsen DA, Nielsen JN, Brandslund I, Poulsen HS, Villingshøj M, Jakobsen A: Lack of the Type III Epidermal Growth Factor Receptor Mutation in Colorectal Cancer. Anticancer Res, 26 (6C): 4889-93, 2006. |
| 118. | Pedersen N, Poulsen TT, Poulsen HS: CreloxP recombination vectors for promoter studies. Electron J Biotechol, 10:315-321, 2007 |
| 119. | Larsen AB, Pedersen MW, Stockhausen M, Grandal MV, van Deurs B, Poulsen HS: Activation of the EGFR target gene EphA2 inhibits EGF-induced cancer cell motility. Molecular Cancer Research, 5(3): 283-293, 2007. |
| 120. | Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS: EGFRvIII escapes downregulation due to impaired internalization and sorting to lysosomes. Carcinogenesis, 28(7): 1408-17, 2007 |
| 121. | Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cellular Signalling, 19 (10) 2013-23, 2007 |
| 122. | Andersen P, Pedersen MW, Woetmann A, Stockhausen MT, Ødum N, Poulsen HS: EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int. J. Cancer, Jan 15; 122(2): 342-9, 2008 |
| 123. | Poulsen TT, Pedersen N, Poulsen HS: A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Therapy 15: 563-575, 2008 |
| 124. | Hansen CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjær A: Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvlll. Chem Biol Drug Des. 72(4): 273-82, 2008. |
| 125. | Poulsen TT, Naizhen X, Poulsen HS, Linnoila IR: Acute damage by naphthalene triggers expression of the neuroendocrine marker PGP9.5 in airway epithelial cells. Toxicol Lett 181: 67-74, 2008. |
| 126. | Poulsen HS, Grunnet K, Sørensen M, Olsen P, Hasselbalch B, Kosteljanetz M, Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncologica. 48(1): 52-8, 2009. |
| 127. | Andersen P, Villingshøj M, Poulsen HS, Stockhausen MT: Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells. Cancer Invest 27 (2): 178-83, 2009 |
| 128. | Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjær A: Identification of novel receptor binding ligands for EFGRvIII using a mixture-based synthetic combinatorial library. Biopolymers. 91(3): 201-206, 2009. |
| 129. | Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS: Specifically targeted gene therapy for small cell lung cancer. Expert Review of Anticancer therapy. 9(4): 437-52, 2009. |
| 130. | Stockhausen MT, Kristoffersen K, Poulsen HS: The Functional role of Notch signaling in human gliomas. Neuro Oncol. Feb; 12(2): 199-211, 2010. |
| 131. | Sørensen M, Gaziel TB, Hasselbalch B, Poulsen HS, Lassen U: Severe skin lesions in patients with glioblastoma multiforme treated with a combination of cetuximab, bevacizumab and irinotecan. European Journal of Clinical & Medical Oncology 1(2): 1-3, 2009. |
| 132. | Larsen AB, Stockhausen M, and Poulsen HS: Cell adhesion and EGFR activation regulate EphA2 expression in cancer. Cellular Signalling 22:636-644, 2010. |
| 133. | Kosteljanetz M, Poulsen HS: Kemoterapi imprægnerede wafers i behandlingen af maligne gliomer i hjernen. En gennemgang af et Cochrane Review. Ugeskrift for Læger, Jan 18; 172(3): 214-217, 2010. |
| 134. | Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS: Targeted cytosine deaminase-uracil phosphoribosyl transferase induces SCLC specific cytotoxicity and tumor growth delay. Clin Cancer Res; April 15; 16(8):2308-19, 2010. |
| 135. | Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS: Cetuximab, Bevacizumab and Irinotecan for Patients with Primary Glioblastoma and Progression after Radiation Therapy and Temozolomide: A Phase II trial. Neuro Oncol. May; 12(5): 508-16, 2010. |
| 136. | Hasselbalch B, Lassen U, Poulsen HS, Stockhausen MT: Cetuximab is insufficient in inhibiting cell growth due to persistent EGFR downstream signalling. Cancer Investigation, May 26. 2010. |
| 137. | Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, Poulsen HS: In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection. Int. J. Nanomedicine.: Aug.9; 5:371-83, 2010. |
| 138. | Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Laursen H, Katita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J: Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signaling in human gliomas. Oncogene.: Sep 9;29(36):5095-102, 2010. |
| 139. | Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U: Prospective evaluation of angiogenic, hypoxic and EGFR related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS, Aug; 118(8): 585-94, 2010. |
| 140. | Olszewski U, Poulsen TT, Ulsberger E, Poulsen HS, Geissler K, Hamilton G: Invitro cytotoxity of combinations of dichloroacetate with anticancer platinum compounds. Clinical Pharmacology: Advances and Applications: 2 1-7, 2010. |
| 141. | Madsen K, Poulsen HS: Needs for support in everyday life for next of kin to brain tumor patients: a systematic literature review. European Journal of Cancer Care. Jan;20(1):33-43, 2011 |
| 142. | Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS: Irinotecan and bevacizumab treatment of recurrence of Glioblastoma Multiforme. Expert Opinion On Pharmacotherapy: Apr; 12(5): 825-33, 2011. |
| 143. | Denholt C, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen, Hansen PR, Gillings N, Kjær A: Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a Positron Emission Tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nuclear Medicine and Biology. May; 38(4): 509-15, 2011. |
| 144. | Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS:PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in Small Cell Lung Cancer expressing mutant p53. Clin Cancer Research, May 1; 17(9): 2830-41, 2011 |
| 145. | Stockhausen MT, Broholm H, Villingshøj M, Kirchhoff M, Gerdes T, Kristoffersen K, Kosteljanetz M, Spang-Thomsen M, and Poulsen HS: Maintenance of EGFR and EGFRvIII expression in an in vivo and in vitro model of human glioblastoma multiforme. Experimental Cell Research: Jul 1; 317(11): 1513-26, 2011. |
| 146. | Gjetting T, Andresen TL, Christensen CL, Poulsen TT, Cramer F, Poulsen HS : A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue. Results in Pharma Sciences 1: 49-56, 2011. |
| 147. | Henriksson R, Asklund T, Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in Glioblastoma Multiforme. J. Neurooncol. : Sep; 104(3): 639-46, 2011. |
| 148. | Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells. Cancer Invest. 29(10):683–691, 2011 |
| 149. | Poulsen HS, Von der Maase H.: MiRNA ved glioblastomer - potentiale og begrænsninger. Ugeskr. Læger, Marts 5; 174(10): 628, 2012 |
| 150. | Nedergaard MK, Hedegaard CJ, Poulsen HS: Targeting the Epidermal growth factor receptor in solid tumor malignancies. BioDrugs: Apr 1; 26(2):83-99. 2012 |
| 151. | Stockhausen MT, Kristoffersen K, Poulsen HS: Notch signaling and brain tumors. Adv Exp Med Biol.727:289-304, 2012 |
| 152. | Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U: A phase II trial with bevacizumab and irinotecanfor patients with primary brain tumors andprogression after standard therapy. Acta Oncol. Jul;51(6):797-804, 2012. |
| 153. | Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS: Single agent- and combination treatment with two targeted gene therapy systems is effective in chemo-resistant small cell lung cancer (SCLC) cells. J Gene Med. Jul;14(7):445-58, 2012 |
| 154. | Cramer F, Christensen CL, Poulsen TT, Badding MA, Dean DA, Poulsen HS: Insertion of a Nuclear Factor Kappa B DNA Nuclear Targeting Sequence potentiatessuicide gene therapy efficacy in lung cancer cell lines. Cancer Gene Therapy Oct;19(10):675-83. 2012 |
| 155. | Bondgaard ALRØ, Poulsen TT, Poulsen HS, Skov BG: Different Expression of EZH2, BMI1 and Ki67 in Low and High Grade Neuroendocrine Tumors of the Lung. Cancer Biomark. 2012;11(2-3):123-8. |
| 156. | |
| 157. | Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: Overexpression of the novel tumor suppressor gene FUS1 suppresses the growth of small cell Lung cancer cells. Clinical and Experimental Pathology. In press. |
| 158. | Lassen U, Sørensen M, Gaziel, TB, Hasselbalch B, Poulsen HS: Phase II study of bevacizumab and Temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Research. In press |
| 159. | Kristoffersen K, Villingshøj M, Stockhausen MT, Poulsen HS: Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biology & Research. In press. |
| 1. | Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N, Poulsen HS, Stahel R, Takahashi T, Twentyman P. Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland. Commentary. Ann Oncology 8: 27 - 36, 1997. |
| 2. | Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N, Poulsen HS, Stahel R, Takahashi T, Twentyman P. Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland. Commentary. Lung Cancer 16: 239 - 257, 1997. |
